ELSEVIER

Contraception

Contraception 68 (2003) 499–500

Author Index
Volume 68
July–December, 2003

Aalborg, A., 377
Abueita, O., 11
Aldrighi, J.M., 27
Alvarez, F., 111
Anderson, F.D., 89
Aneblom, G., 117
Ashok, P.W., 335

Bahamondes, L., 27, 55, 105
Baird, D.T., 203
Ballentine, J.M., 377
Barlow, W.E., 177
Barnhart, K.T., 273
Beksinska, M.E., 339
Bennett, W., 261
Bilian, X., 439, 447
Biswas, A., 189
Blum, J., 117
Boise, R., 377
Borenstein, J., 3
Brache, V., 111
Brechin, S., 327
Brown, A., 203
Bygdeman, M., 495
Byrd, T.L., 281

Cabral, R., 377
Callejo, J., 183
Camargo, R.P.S., 105
Cameron, S., 203
Camp, S.L., 309
Chaikummao, S., 47
Chan, C.-w.C., 269
Cheng, L., 447
Cheung, W., 97
Chiou, C.-F., 3
Coggins, C., 47
Cohen, A.F., 195
Creinin, M.D., 365, 373
Croxatto, H.B., 483
Curtis, K.M., 377

D'Anella, A., 261
Dayal, M.B., 273
de Kroon, C.D., 101
de Villemeur, M., 39
de Visser, S.J., 195
Dersjant-Roorda, M., 101
Dhawan, L., 453
di Capua, E., 35
Díaz, J., 183
Dorflinger, L., 70
Dow, J., 335

Elias, C.J., 47
Ellertson, C., 47, 70

Faúndes, A., 55, 111
Fang, R.-Y., 289
Farley, T.M.M., 339
Fathalla, M.F., 397
Fazano, F., 55
Ferraz do Lago, R., 105
Flett, G.M.M., 335
Foster-Rosales, A., 345, 353
Fox, M.C., 365
Fraser, A.B., 233
Fukazawa, I., 195
Fulcheri, E., 35

Gainer, E., 117
Gallo, M.F., 233, 319
García, R.M., 183
Gemzell-Danielsson, K., 471
Ghosh, D., 453
Glasier, A., 327
Gogaeva, E.V., 239
Golousenko, I.J., 239
Golubeva, O.N., 239
Grimes, D.A., 233, 319
Guidozzi, F., 339
Gupta, A., 61
Gupta, G., 135
Gupta, S., 61

Hait, H., 89
Hall, L.C., 253
Hamoda, H., 335
Han, C.-S., 297
Harwood, B., 365
Hassan, D.F., 27
He, Q.-J., 289
Heber, W., 211
Heikinheimo, O., 421, 427
Heng, Z., 439, 447
Hill, L.J., 211
Ho, P.-C., 97, 269
Howe, M., 211
Hu, Z.-Y., 297
Hwang, A.C., 1, 73, 157, 231, 307

Ichikawa, L.E., 177
Inaba, T., 65
Isaacs, J.N., 373

Jansen, F.W., 101
Jin, X., 297
John, L., 11
Jorge, A., 111

Kahn, J.A., 385
Kawate, N., 65
Kekkonen, R., 421
Keshri, G., 303
Khader, Y.S., 11
Khaleel, A., 125
Khillare, A., 225
Kilmarx, P.H., 47
Kleinschmidt, I., 339
Knight, K., 3
Kollar, L.M., 385
Koontz, S.L., 345, 353
Kumar, A.S., 253
Kunii, O., 125

Lähteenmäki, P., 421
LaCroix, A.Z., 177
Lakshmi, V., 303
Lalitkumar, P.G.L., 453
Larsson, M., 117
Lee, S.W.H., 97
Leminen, R., 427
Leon, K., 345, 353
LePage, A., 253
Li, C.-f.I., 269
Lichtenberg, E.S., 211
Lim, P.C., 253
Limpakarnjanarat, K., 47
Linan, C., 439
Liu, Y.-X., 297
Lutwick, A., 117
Luukkainen, T., 31

Machielsen, C.S.M., 195
Maikhuri, J.P., 135
Mandl, I., 471
Manopaiboon, C., 47

0010-7824/03/$ – see front matter © 2003 Elsevier Inc. All rights reserved.

Marcella, S., 261
Marions, L., 471
Mastro, T.D., 47
Mejevitinova, E.A., 239
Mikolajczyk, R., 69
Minnis, A.M., 19
Mizuta, Y., 65
Molina de Perez, O., 345, 353
Monga, M., 219
Monteiro, I., 105
Moore, A.M., 281
Moore, K., 359
Morrow, S., 203
Munuce, F., 55
Murthy, A.S., 365

Nørgaard, M., 247
Nagase, T., 125
Nascimento, J.A.A., 55
Nesheim, B.-I., 117
Neuteboom, K., 101
Nilas, L., 247
Nymoen, P., 117

Oda, K., 3
Oehler, J., 427
Ojha, P., 135
Ott, S.M., 177

Padian, N.S., 19
Pakarinen, P., 31
Peipert, J.F., 211
Penney, G., 327
Perrotti, M., 27, 105
Petersen, R., 377
Petraitis, C., 261
Petta, C.A., 27
Piaggio, G., 431, 439, 447, 477, 489
Portugal, N., 117
Potter, J.E., 281
Potter, W.D., 39
Prilepskaya, V.N., 239

Rørbye, C., 247
Ragni, N., 35
Raine, R., 327
Raine, T., 19, 309
Rajasekaran, M., 219
Ranta, S., 427
Reed, S.D., 177
Rees, H.V., 339
Reid, L.M., 365
Reyes, E., 3
Rice, J., 11
Rithaporn, T., 219
Roy, A.C., 189
Ruiz, A., 183

Sawada, T., 65
Scholes, D., 177
Schulz, K.F., 233, 319
Sengupta, J., 453
Serov, V.N., 239
Shields, W.C., 1, 73, 157, 231, 307
Shrivastav, T.G., 225
Simões, J.A., 105
Singh, M.M., 303
Sitruk-Ware, R., 409
Slap, G.B., 385
Smit, J.A., 339
Sousa, M.H., 111
Spinnato II, J.A., 69
Spitz, I.M., 409
Stanford, J.B., 69
Stewart, F.H., 1, 73, 157, 231, 307

Tamada, H., 65
Tang, O.S., 97
Templeton, A., 335
Tharawan, K., 47
The Seasonale-301 Study Group, 89
Tiwary, A.K., 61
Toivonen, J., 31
Toverud, E.-L., 117
Truitt, S.T., 233
Trussell, J., 3, 70
Tyden, T., 117

Uchida, E., 195
Uchida, N., 195
Udani, J., 3
United Nations Development Programme/United Nations Population Fund/World Health Organization/World Bank Special Programme of Research, Development and Research Training in Human Reproduction, Task Force on Long-acting Systemic Agents for Fertility Regulation, 159

van den Heuvel, M.W., 195
van Doorn, M.B.A., 195
van Vliet-Daskalopoulou, E., 195
Vestermark, V., 247
Viegas, O.A.C., 189
Vilar, D., 117
von Hertzen, H., 427, 431, 439, 447, 477, 489

Wakai, S., 125
Wallace, J., 3
Wang, W.-F., 289
Weiss, E., 359
Westhoff, C., 75
Wheeler, J., 273
Wilkerson, D.S., 309
Williams, A., 203
Williams, C.J., 273
Wimberly, Y.H., 385
Winikoff, B., 117
Wu, H.-H., 289

Xiao, B., 431, 477, 489

Yaglov, V.V., 239
Yang, B., 289
Yoshida, C.K., 377

Zhang, X.-S., 297
Zhang, Z.-H., 297
Zhao, H., 431, 477, 489
Zharav, E.V., 239
Zou, R.-J., 297

ELSEVIER

Contraception

Contraception 68 (2003) 501–503

Subject Index
Volume 68
July–December, 2003

Abstinence-only programs, ARHP editorial, 231
Abstracts, ARHP 2003 conference. Advances in Reproductive Health session, 239
Adolescent beliefs, fertility and infertility, 385
ARHP 2003 conference, Advances in Reproductive Health session abstracts, 139
Association of Reproductive Health Professionals (ARHP) editorial,
  abstinence-only programs, 231
  keeping abortion legal, 307
  reproductive health care, 73
  Title X, Public Health Service Act, 1
  war on words, 157

Bacterial vaginosis and other cervicovaginal infections, prevalence in IUD users, 105
Bcl-1 and Bax, involvement in cryptorchidism (monkey), 297
Bone mineral density, effect of OC use, 177

Cervical priming, effect of isosorbide mononitrate, 269
Clinical trial, mifepristone EC, 431
Complications following IUD insertion, TCu-380A, 105
Condom,
  clinical evaluation of polyurethane material, 39
  nonlatex vs. latex, 319
Consensus statement, mifepristone to reduce unwanted pregnancy, 395
Contraceptive method choice, determinants, 19
Contraceptive potential, immediate preovulatory phase mifepristone, 203
Contraceptive practice, WHO Selected Practice Recommendations for Contraceptive Use, 327
Contraceptive procurement, cross-border (US-Mexico), 281
Contraceptive use, obstacles, 125
Contraceptives, economic analysis, 3
Copper-releasing IUD, insertion after abortion, 31
Copper-T IUD, effect on weight variation, 27
Counseling at time of pregnancy testing, 377
Cross-border (US-Mexico) contraceptive procurement, 281
Cryptochidism, relationship to Bcl-2 and Bax expression (monkey), 297
Curcumin,
  diferuloylmethane compound, 219
  effect on sperm, 219

Depot-medroxyprogesterone acetate (DMPA),
  efficacy and safety, 75
  FSH levels in older women, 339
Determinants, contraceptives method choice, 19
DL111-IT + mifepristone, termination of pregnancy (animals), 289
DL111-IT + mifepristone + misoprostol, termination of pregnancy (animals), 289
DMPA (depot-medroxyprogesterone acetate)
Dysmenorrhea, effect of ethinyl estradiol + desogestrel, 183

EC (emergency contraception)
EC availability, over-the-counter, 309
EC effectiveness, estimating day of ovulation, 69
EC pills,
  "behind the counter", 253
  nonprescription access, 117, 253, 309
Economic analysis, contraceptives for women, 3
Effectiveness, mifepristone EC, 439
Efficacy and safety, depot-medroxyprogesterone acetate, 75
Electronic mail (e-mail) reminder, effect on OC compliance, 365
Emergency contraception (EC),
  knowledge and attitudes of pharmacists, 261
  levonorgestrel, 117, 309
  mifepristone, 431, 439, 447, 453, 471
Endometrial sampling, manual vacuum aspiration, 353
Estradiol cypionate + medroxyprogesterone acetate, effect on hemostasis, 159
Estradiol valerate + norethisterone enanthate, effect on hemostasis, 159
Ethinyl estradiol + desogestrel,
  effect on dysmenorrheal, 183
  effect on skin, 239
Ethinyl estradiol + levonorgestrel, efficacy and safety of extended cycle OC, 89
Ethinyl estradiol + noresthisterone, effect on hemostasis, 159
Ethinyl estradiol + Org 30659, pharmacokinetics and safety, 195
Ethnic differences, pharmacokinetics and safety of ethinyl estradiol + Org 30659, 195
Etonogestrel, effect on serum lipids, 189
Extended cycle OC, Seasonale®, 89

Fadrozole hydrochloride,
  effect on implantation (rat), 65
  non-steroidal aromatase inhibitor, 65

0010-7824/03/$ – see front matter © 2003 Elsevier Inc. All rights reserved.

Fertility and infertility, adolescent beliefs, 385
Fertility regulation, use of mifepristone, 401
Follow-up visits, effectiveness after IUD insertion, 101
FSH (follicle-stimulating hormone)
FSH levels, older women using injectable contraceptives, 339

H_2-receptor antagonists, spermicidal efficacy, 61
Healthcare providers and patients, miscommunication, unintended pregnancy, 373
Hemostasis,
  effect of estradiol cypionate + medroxyprogesterone acetate, 159
  effect of estradiol valerate + norethisterone enanthate, 159
  effect of ethinyl estradiol + norethisterone, 159
HIV transmission risk, knowledge and perceptions, 47
Hormonal contraception during lactation, 233

Immediate postabortion insertion, levonorgestrel-releasing IUS vs. copper-releasing IUD, 31
Implant contraceptives,
  ethonogestrel, 189
  levonorgestrel, 189
  Norplant, 111
Implantation, effect of fadrozole hydrochloride (rat), 65
Incomplete abortion treatment, manual vacuum aspiration, 345
Injectable contraceptives,
  depot-medroxyprogesterone acetate, 75, 339
  estradiol cypionate + medroxyprogesterone acetate, 159
  estradiol valerate + norethisterone enanthate, 159
  norethisterone enanthate, 339
Insertion site of Norplant implants, local side effects, 111
Internet information on IUD, content and quality, 359
Intrauterine device (IUD),
  copper-T, 27
  effects on pregnancy evolution and fetus, 35
  information on internet, 359
  Nova T, 31
  TCu-380A, 105
Intrauterine system (IUS), levonorgestrel-releasing, 31
Isosorbide monontitrate, effect on cervical priming, 269
IUD (intrauterine device)
IUD in situ, effect on pregnancy, 35
IUD insertion, effectiveness of follow-up visits, 101
IUD users, prevalence of vaginal infections, 105
IUS (intrauterine system)

Knowledge and attitudes of pharmacists, emergency contraception, 261
Knowledge and perceptions, HIV transmission risk, 47

Lactation, effect of hormonal contraception, 233
Lactobacillus colonies, effect of spermicides, 135
Latex vs. nonlatex condom, 319
Legal abortion, ARHP editorial, 307
Levonorgestrel,
  effect on serum lipids, 189
  effect on spermatozoa, 55
Levonorgestrel EC,
  nonprescription access, 117
  over-the-counter availability, 309
Levonorgestrel-releasing IUD, insertion after abortion, 31
Lipid parameters,
  effect of etonogestrel, 189
  effect of levonorgestrel, 189
Local side effects, Norplant contraceptive implants, 111
Luteal phase contraception, mifepristone, 483
Luteal phase treatment, mifepristone + misoprostol, 477

Manual vacuum aspiration,
  endometrial sampling, 353
  incomplete abortion treatment, 345
Mechanism of action,
  mifepristone EC, 471
  mifepristone EC (monkey), 453
Medical abortion,
  criteria for success, 247
  mifepristone + gemeprost, 247
  mifepristone + misoprostol, 335
  sublingual misoprostol, 97
Melia azedarach Linn., pregnancy interceptive activity (rat), 303
Menstrual induction,
  use of mifepristone, 495
  use of mifepristone + misoprostol, 489
Meta-analysis,
  different doses of mifepristone EC, 447
  OC use and risk of myocardial infarction, 11
Methohexital, general anesthetic for vacuum abortion, 211
Mifepristone,
  contraceptive potential in immediate preovulatory phase, 203
  pharmacokinetics, 421, 427
  toxicology and safety (animals), 409
  use for luteal phase contraception, 483
  use for menstrual induction, 495
  use in fertility regulation, 401
Mifepristone + gemeprost, medical abortion, 247
Mifepristone + misoprostol,
  luteal phase treatment, 477
  medical abortion, 335
  termination of pregnancy (animals), 289
  use for menstrual induction, 489
Mifepristone EC,
  clinical trial, 431
  effectiveness, 439
  mechanism of action, 471
  meta-analysis of different doses, 447
  multiparametric study of action (monkey), 453
Mifepristone to reduce unwanted pregnancy, consensus statement, 395
Miscommunication, healthcare providers and patients, unintended pregnancy, 373
Misoprostol,
  sublingual administration, 97
  sublingual vs. vaginal administration, 335
Modern contraceptive use, obstacles, 125
Multiparametric study of action, mifepristone EC (monkey), 453

Myocardial infarction risk, effect of OC use, 11

Neem leaf extract, effect on spermatozoa, 225
Nonlatex vs. latex condoms, 319
Nonoxynol-9,
  effect on lactobacillus colonies, 135
  effect on uterus epithelium (mouse), 273
Nonprescription access, EC pills, 117, 253, 309
Norethisterone enanthate, FSH levels in older women, 339
Norplant, local side effects, 111

Obstacles to modern contraceptive use, 125
OC compliance, effect of electronic mail (e-mail) reminder, 365
OC use,
  effect on bone mineral density, 177
  risk of myocardial infarction, 11
Older women, FSH levels following use of injectable contraceptives, 339
Online information on IUD, content and quality, 359
Oral contraceptive (OC),
  ethinyl estradiol + desogestrel, 183
  ethinyl estradiol + levonorgestrel, 89
  ethinyl estradiol + norethisterone, 159
  ethinyl estradiol + Org 30659, 195
  triphasic ethinyl estradiol + desogestrel, 239
Org 30659 [(17α)-17hydroxy-11-methylene-19-norpregna-4, 15-dien-20-7n-3-one]
Over-the-counter availability, levonorgestrel EC, 309

Pharmacists' knowledge and attitudes, emergency contraception, 261
Pharmacodynamics, mifepristone (animals), 409
Pharmacokinetics,
  ethinyl estradiol + Org 30659, 195
  mifepristone, 421, 427
  mifepristone (animals), 409
Polyurethane condom, clinical evaluation, 39
Pregnancy despite IUD, 35
Pregnancy evolution and fetus, effect of IUD in situ, 35
Pregnancy interceptive activity, *Melia azedarach* Linn. (rat), 303
Preovulatory phase mifepristone, contraceptive potential, 203
Propofol, general anesthetic for vacuum abortion, 211

Reducing the need for abortion, editorial, 397
Reproductive health care, ARHP editorial, 73
Reproductive health counseling, time of pregnancy testing, 377

Safety, depot-medroxyprogesterone acetate, 75
Safety studies, mifepristone (animals), 409
Sapindus saponins, effect on lactobacillus colonies, 135
Seasonale®, efficacy and safety, 89
Selected Practice Recommendations for Contraceptive Use, World Health Organization, 327
Side effects profile, mifepristone EC, 439
Skin, effect of ethinyl estradiol + desogestrel, 239
Spermatozoa,
  effects of curcumin, 219
  effect of H_2-receptor antagonists, 61
  effect of levonorgestrel, 55
  effect of neem leaf extract, 225
Spermicides, effect on lactobacillus colonies, 135
Sublingual misoprostol, use for termination of pregnancy, 97
Sublingual vs. vaginal misoprostol, abortion after mifepristone administration, 335
Success criteria, medical abortion, 247

Termination of pregnancy, DL111-IT + mifepristone + misoprostol (animals), 289
Title X, Public Health Service Act, ARHP editorial, 1
Toxicology studies, mifepristone (animals), 409

Unintended pregnancy, miscommunication between healthcare providers and patients, 373
Uterine epithelium, effect of nonoxynol-9 (mouse), 273

Vacuum abortion general anesthetics, propofol vs. methohexital, 211

War on words, ARHP editorial, 157
Weight changes, use of copper-T IUD, 27
WHO (World Health Organization)
WHO Selected Practice Recommendations for Contraceptive Use, 327